• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Reported Late Wednesday, Biotech Acquisition Company Announces Plan For New Sponsor To Make Additional Contributions To Trust Account Upon Approval Of Proposed Extension Amendment

    1/5/23 12:31:22 AM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOT alert in real time by email

     Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding and is not redeemed in connection with the Extension.

    The amount deposited per share will depend on the number of public shares that remain outstanding after redemptions in connection with the Extension and the length of the extension period that will be needed to complete an initial business combination.

    If the Extension is implemented, the Company plans to maintain the remaining amount in the Trust Account in an interest-bearing demand deposit account at a bank.

    The Company also notes that as it is a Cayman Islands exempted company, unless and until it redomiciles into the United States, it is not affected by the current uncertainty surrounding excise tax liabilities and the implementation of the Inflation Reduction Act of 2022.

    About Biotech Acquisition Company

    Biotech Acquisition Company raised $230 million in its initial public offering in January 2021. The Class A ordinary shares and warrants of the Company trade on the Nasdaq Capital Market under the symbols "BIOT" and "BIOTW," respectively. The Company is a blank check company, incorporated as a Cayman Islands exempted company, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses.

    Get the next $BIOT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOT
    SEC Filings

    View All

    SEC Form 424B3 filed by Biotech Acquisition Company

    424B3 - Relativity Holdings Inc. (0002072188) (Filer)

    3/5/26 5:00:17 PM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Biotech Acquisition Company

    EFFECT - Relativity Holdings Inc. (0002072188) (Filer)

    12/4/25 12:15:08 AM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS AM filed by Biotech Acquisition Company

    POS AM - Relativity Holdings Inc. (0002072188) (Filer)

    11/25/25 4:48:49 PM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotech Acquisition Company Announces Liquidation

    New York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) --  Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the "Charter") and will redeem

    2/1/23 7:50:00 PM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding an

    1/4/23 5:51:00 PM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blade Therapeutics to Participate in "Drug Development in Pulmonary Medicine" Panel Discussion at 2022 BTIG Biotechnology Conference

    Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the "Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need" panel discussion on Tuesday, August 9, 2022, 1:00 pm (ET), during the 2022 BTIG Biotechnology Conference, August 8 – 9, in New York City. Blade's lead investigational medicine is cudetaxestat, a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial i

    8/1/22 8:00:00 AM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOT
    Leadership Updates

    Live Leadership Updates

    View All

    Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development

    Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development. In this role, Dr. Elmankabadi will oversee strategy and execution of Blade's clinical development programs. "Dr. Elmankabadi has an extensive track record driving drug development from proof-of-concept through launch across multiple therapeutic areas," said Wendye Robbins, M.D., president and CEO of Blade. "I am thrilled to welcome Dr. Elmankabadi to the Blade team as we seek to advance our clinical-stage pipeline t

    11/18/21 8:00:00 AM ET
    $AMGN
    $BIOT
    $FGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)

    SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

    2/14/24 9:12:34 AM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)

    SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

    2/14/23 10:50:25 AM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Biotech Acquisition Company

    SC 13G - Biotech Acquisition Co (0001825413) (Subject)

    2/14/23 10:35:55 AM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care